FORA Capital LLC Acquires Shares of 17,332 Pfizer Inc. $PFE

Key Points

• FORA Capital LLC acquired 17,332 shares of Pfizer Inc., valued at approximately $439,000, making this a significant new stake in the biopharmaceutical firm during the first quarter.
• Analysts have mixed views on Pfizer, with target prices ranging from $25 to $33, while the stock holds an average rating of "Hold" and a consensus price target of $28.12.
• Pfizer announced a quarterly dividend of $0.43 per share, yielding 7.0%, which reflects a strong commitment to returning value to shareholders.

FORA Capital LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 17,332 shares of the biopharmaceutical company's stock, valued at approximately $439,000.

Other large investors have also added to or reduced their stakes in the company. Clarity Asset Management Inc. purchased a new position in Pfizer during the fourth quarter valued at $27,000. Gould Capital LLC increased its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer in the 1st quarter worth $27,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the 1st quarter worth $28,000. Finally, North Capital Inc. bought a new stake in shares of Pfizer in the 1st quarter worth $28,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Jefferies Financial Group lifted their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Morgan Stanley lifted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Trading Down 1.9%

Shares of PFE stock opened at $24.60 on Friday. The company has a market cap of $139.86 billion, a PE ratio of 13.09, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52. The stock's 50 day simple moving average is $24.78 and its two-hundred day simple moving average is $24.39. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer's dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.